Abstract:Background Systemic sclerosis (SSc) is a chronic inflammatory disease with complex pathogenesis. The role of regulatory T cells (Tregs) in the development of SSc has started being studied during the last decade with new aspects being disclosed continuously. Although there is a general agreement in the medical literature regarding the decreased functional capacity of circulating Tregs in SSc, the alteration of absolute number of Treg cells as well as orther CD4 +T lymphocyte subsets in SSc is still unclear. Objectives The aim of the present study was to explore the absolute number status of CD4 +T subsets in peripheral blood of patients with SSc using our modified flow cryometric method and investigate whether the imbalance of Th17 and Treg cells can be corrected by supplementing low dose interleukin −2 (IL-2). Methods The peripheral CD4 +T subsets from 54 patients with SSc and 30 healthy control subjects were analysed. The patients were divided into the untreated group (n=29) and treated group (n=25). The patients were also divided into group A (n=28) who only used low-dose glucocorticoids (GCS), and group B (n=26) who also used immunosuppressant cyclophosphamide (CYC), methotrexate (MTX), leflunomide (LEF) or mycophenolate mofetil (MMF). In addition, 21 patients from 54 patients, given a small dose of IL-2 (50WIU) treatment for a 5 day course, divided into pre-treatment group and post-treatment group. Directly using the results from flow cytometry combined with internal standard beads, absolute number of peripheral CD4 +T subsets from the subjects in each group were calculated. Results Although there were some changes among CD4 +T cell subsets in peripheral blood from these SSc patients, the major alteration was the reductions of Treg cell absolute number. Compared with the normal controls, the number of CD4+CD25+FOXP3+Treg cells were significantly decreased in all patients (p=0.001), in untreated group (p=0.029), in treated group (p=0.029), in group A (p=0.006) and in group B (p=0.004). The ratio of Th17/Treg in total patients (p=0.008) and group B (p=0.001) were significantly higher than that in normal control group, and the group B was significantly higher than the group A (p=0.032). Moreover, the number of Th17 cells in group B was significantly higher than that in group A (p=0.023). After IL-2 treatment, the absolute number of CD4+CD25+FOXP3+Treg cells (p 0.05). Since Th17 cells increases significantly lower than Treg cells, so their ratio decreases significantly (p=0.001) to get re-balance. Conclusions The absolute number of peripheral CD4 +CD25+FOXP3+Treg cells decreased in untreated patients, indicating that this reduction arising from the disease itself. Our findings suggest that SSc progression is associated with the absolute decrease of peripheral Treg cells. Although there was no statistically significant different, absolute number of the Treg cells trended to decrease in patients treated with immunosuppressive agents. The use of IL-2 can effectively up-regulate Treg cells as well as increase Th17 to a certain extent, which restores the balance of Th17/Treg cells, but the long-term effect needs further investigation. Disclosure of Interest None declared

Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Inflammatory Response of Monocytes/Macrophages in Patients with Systemic Sclerosis

FRI0450 Associations of alterations of peripheral regulatory t and th17 absolute cell numbers with clinical features in patients with systemic sclerosis

DIFFERENTIAL EXPRESSION OF PERIPHERAL CD4+T CELLS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND MIXED CONNECTIVE TISSUE DISEASE

Non-classical circulating monocytes expressing high levels of microsomal prostaglandin E2 synthase-1 tag an aberrant IFN-response in systemic sclerosis

THU0412 Absolute reduction of peripheral cd4 + regulatory t cell subset of patients with systemic sclerosis and its restoration by short-term and low dose il-2 treatment

Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis

Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis

Dendritic cells drive profibrotic inflammation and aberrant T cell polarization in systemic sclerosis

Immune Profiling of Patients with Systemic Sclerosis through Targeted Proteomic Analysis

Extended Inflammation Parameters (EIP) as Markers of Inflammation in Systemic Sclerosis

Serum IL-17 and TNFα as prognostic biomarkers in systemic sclerosis patients: a prospective study

Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases

A-100 Selected pro-and anti-inflammatory cytokine serum concentrations in different clinical forms of multiple sclerosis

Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion

Alterations in peripheral T‐ and B‐cell subsets in patients with systemic sclerosis

Relationships of Peripheral Blood Th17 and Regulatory T Cells with Disease Activity in Patients with Systemic Sclerosis

Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis

Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis

Microchimerism and Systemic Sclerosis